Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
NCT00634205
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
45
Enrollment
OTHER
Sponsor class
Conditions
Malignant Mesothelioma
Interventions
DRUG:
Valproate plus doxorubicin
Sponsor
European Lung Cancer Working Party